SML3182

Eltrombopag

≥98% (HPLC)

• Synonym(e): (Z)-3′-(2-(1-(3,4-Dimethylphenyl)-3-methyl-5-oxo-1H-pyrazol-4(5H)-ylidene)hydrazinyl)-2′-hydroxybiphenyl-3-carboxylic acid, 3′-[(2Z)-2-[1-(3,4-Dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazinyl]-2′-hydroxy[1,1′-biphenyl]-3-carboxylic acid, SB 497115, SB-497115, SB497115
• Empirische Formel (Hill-System): C₂₅H₂₂N₄O₄
• CAS-Nummer: 496775-61-2
• Molekulargewicht: 442.47
• MDL-Nummer: MFCD20926253
• UNSPSC-Code: 12352200
• NACRES: NA.77

Eigenschaften

• Qualitätsniveau: 100
• Assay: ≥98% (HPLC)
• Form: powder
• Farbe: faint yellow to dark orange
• Löslichkeit: DMSO: 2 mg/mL, clear
• Lagertemp.: 2-8°C
• SMILES String: OC1=C(C=CC=C1N/N=C2C(C)=NN(C/2=O)C3=CC(C)=C(C=C3)C)C4=CC=CC(C(O)=O)=C4

Beschreibung

Biochem./physiol. Wirkung

Eltrombopag is an orally active nonpeptide thrombopoietin receptor (TpoR) agonist that selectively induces STAT activation and proliferation (EC50 = 270 & 30 nM, respectively) of hToR-transfected, but not non-transfected, BAF3 cells. Eltrombopag increases the differentiation of primary human CD34(+) bone marrow cells into CD41(+) megakaryocytes ex vivo (EC50 = 100 nM) and exhibits thrombopoietic activity in chimpanzees in vivo (10 mg/kg/day p.o.).

Sicherheitshinweise

• Piktogramme: GHS08,GHS05,GHS07,GHS09
• Signalwort: Danger
• H-Sätze: H302,H318,H373,H411
• P-Sätze: P260 - P273 - P280 - P301 + P312 - P305 + P351 + P338 - P314
• Gefahreneinstufungen: Acute Tox. 4 Oral - Aquatic Chronic 2 - Eye Dam. 1 - STOT RE 2
• Lagerklassenschlüssel: 11 - Combustible Solids
• WGK: WGK 3
• Flammpunkt (°F): Not applicable
• Flammpunkt (°C): Not applicable